IVERIC bio, Inc.
ISEEDelisted Jul 11, 2023- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001410939
IVERIC bio, Inc. was delisted on Jul 11, 2023; its insiders filed their last Form 4 on Jul 13, 2023; 256 institutions reported holding it in 13F filings for Q2 2023, worth $5.33B in total; Soros Fund Management was the only superinvestor holding it.
13F holders, Q1 2021
Institutional positions in IVERIC bio, Inc. as of Mar 31, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 115
- No complete 13F data for Q4 2020
- Shares held
- 80.2M
- No complete 13F data for Q4 2020
- Total value
- $495.6M
- No complete 13F data for Q4 2020
Holders and value by quarter
Institutions reporting ISEE on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 256 | $5.33B |
| Q1 2023 | 223 | $3.58B |
| Q4 2022 | 225 | $3.15B |
| Q3 2022 | 213 | $2.26B |
| Q2 2022 | 185 | $1.15B |
| Q1 2022 | 163 | $2.02B |
| Q4 2021 | 175 | $2.00B |
| Q3 2021 | 150 | $1.68B |
| Q2 2021 | 128 | $536.9M |
| Q1 2021 | 115 | $495.6M |
Institutions, Q1 2021
Shares, value and share of portfolio for each institution holding IVERIC bio, Inc..
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Acuta Capital Partners, LLC | 1,579,093 | $9.76M | 3.52% | – | – |
| Commodore Capital LP | 1,729,041 | $10.7M | 4.26% | – | – |
| Price T Rowe Associates Inc | 2,163,192 | $13.4M | 0.00% | – | – |
| Samsara BioCapital, LLC | 2,372,476 | $14.7M | 2.95% | – | – |
| Frazier Management LLC | 2,544,500 | $15.7M | 1.26% | – | – |
| Yiheng Capital Management, L.P. | 2,784,083 | $17.2M | 0.78% | – | – |
| Soleus Capital Management, L.P. | 3,380,979 | $20.9M | 3.76% | – | – |
| State Street Corp | 3,694,983 | $22.8M | 0.00% | – | – |
| Vanguard Group Inc | 4,225,287 | $26.1M | 0.00% | – | – |
| Perceptive Advisors LLC | 4,585,512 | $28.3M | 0.38% | – | – |
| Deerfield Management Company, L.P. (Series C) | 5,767,409 | $35.6M | 0.75% | – | – |
| Vivo Capital, LLC | 5,966,527 | $36.9M | 1.30% | – | – |
| RTW Investments, LP | 6,722,624 | $41.5M | 0.65% | – | – |
| BlackRock Inc. | 7,059,634 | $43.6M | 0.00% | – | – |
| Avoro Capital Advisors LLC | 7,250,000 | $44.8M | 0.77% | – | – |